Alan Sharpe

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 303 citations

Comparisons between FLUENT and ADMS for atmospheric dispersion modelling

A.M. Riddle, David Carruthers, Alan Sharpe et al. · Atmospheric Environment · 2003 · 248 citations

Meteorology, Atmospheric Condition, Engineering +5

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

James Sherwood, Claire Corcoran, Helen Brown et al. · PLoS ONE · 2016 · 145 citations · Full text

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

Helen K. Angell, J. Lee, Kyung‐Min Kim et al. · OncoImmunology · 2018 · 61 citations · Full text

Cancer Immunosurveillance, Pd-l1 Expression, Pd-l1 Segment +14

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

Anne-Marie Boothman, Marietta Scott, M. Ratcliffe et al. · Journal of Thoracic Oncology · 2019 · 56 citations · Full text

Advanced Nsclc, Prior Therapy, Medicine +8